Babesia: An Emerging Infectious Threat in Transfusion Medicine

PLoS Pathogens

Volumn 9, Issue 7, 2013, Pages

  Lobo, Cheryl A ^a   Cursino Santos, Jeny R ^a   Alhassan, Andy ^a   Rodrigues, Marilis ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; AZITHROMYCIN; CLINDAMYCIN; QUININE;

ANTIMICROBIAL THERAPY; ARTICLE; BABESIA; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; HUMAN; IMMUNOFLUORESCENCE TEST; NONHUMAN; PARASITE LOAD; PATHOGEN CLEARANCE; PIROPLASMOSIS; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RISK FACTOR;

EID: 84884769244     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003387     Document Type: Article

References (22)

1. Lantos PM, Krause PJ, (2002) Babesiosis: similar to malaria but different. Pediatr Ann 31: 192-197.
2. Leiby DA, (2011) Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti. Clin Microbiol Rev 24: 14-28.
3. Conrad PA, Kjemtrup AM, Carreno RA, Thomford J, Wainwright K, et al. (2006) Description of Babesia duncani n.sp. (Apicomplexa: Babesiidae) from humans and its differentiation from other piroplasms. Int J Parasitol 36: 779-789.
4. Herwaldt B, Persing DH, Precigout EA, Goff WL, Mathiesen DA, et al. (1996) A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med 124: 643-650.
5. Gigandet L, Stauffer E, Douet V, Rais O, Moret J, et al. (2011) Prevalence of three zoonotic Babesia species in Ixodes ricinus (Linne, 1758) nymphs in a suburban forest in Switzerland. Vector Borne Zoonotic Dis 11: 363-366.
6. Gray JS, (2006) Identity of the causal agents of human babesiosis in Europe. Int J Med Microbiol 296 (Suppl 40):: 131-136.
7. Kjemtrup AM, Conrad PA, (2000) Human babesiosis: an emerging tick-borne disease. Int J Parasitol 30: 1323-1337.
8. Ruebush TK 2nd, Juranek DD, Chisholm ES, Snow PC, Healy GR, et al. (1977) Human babesiosis on Nantucket Island. Evidence for self-limited and subclinical infections. N Engl J Med 297: 825-827.
9. Gubernot DM, Nakhasi HL, Mied PA, Asher DM, Epstein JS, et al. (2009) Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion 49: 2759-2771.
10. Leiby DA, (2011) Transfusion-associated babesiosis: shouldn't we be ticked off? Ann Intern Med 155: 556-557.
11. Krause PJ, Spielman A, Telford SR 3rd, Sikand VK, McKay K, et al. (1998) Persistent parasitemia after acute babesiosis. N Engl J Med 339: 160-165.
12. Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, et al. (2010) Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis 50: 381-386.
13. Wittner M, Rowin KS, Tanowitz HB, Hobbs JF, Saltzman S, et al. (1982) Successful chemotherapy of transfusion babesiosis. Ann Intern Med 96: 601-604.
14. Krause PJ, Lepore T, Sikand VK, Gadbaw J Jr, Burke G, et al. (2000) Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 343: 1454-1458.
15. Tonnetti L, Eder AF, Dy B, Kennedy J, Pisciotto P, et al. (2009) Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 49: 2557-2563.
16. Gerber MA, Shapiro ED, Krause PJ, Cable RG, Badon SJ, et al. (1994) The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis 170: 231-234.
17. Eberhard ML, Walker EM, Steurer FJ, (1995) Survival and infectivity of Babesia in blood maintained at 25 C and 2-4 C. J Parasitol 81: 790-792.
18. Johnson ST, Van Tassell ER, Tonnetti L, Cable RG, Berardi VP, et al. (2013) Babesia microti real-time polymerase chain reaction testing of Connecticut blood donors: potential implications for screening algorithms. Transfusion E-pub ahead of print. doi:10.1111/trf.12125.
19. Young C, Chawla A, Berardi V, Padbury J, Skowron G, et al. (2012) Preventing transfusion-transmitted babesiosis: preliminary experience of the first laboratory-based blood donor screening program. Transfusion 52: 1523-1529.
20. Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, et al. (2011) Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 51: 2367-2376.
21. Reddy HL, Doane SK, Keil SD, Marschner S, Goodrich RP, (2013) Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 53 (Suppl 1):: 131S-136S.
22. Tonnetti L, Thorp AM, Reddy HL, Keil SD, Goodrich RP, et al. (2012) Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 53: 860-867.